Developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need
Location: United States, California, San Francisco
Total raised: $141.6M
Founded date: 2016
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.02.2023 | - | $53.6M | - |
| 20.02.2020 | Series B | $88M | Omega Fund... |
Mentions in press and media 12
| Date | Title | Description |
| 10.02.2023 | Spruce Biosciences Announces $53.6 Million Private Placement Financing | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Feb. 9, 2023– Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significan... |
| 09.02.2023 | Spruce Biosciences Announces $53.6 Million Private Placement Financing | South San Francisco, CA — Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today anno... |
| 22.03.2021 | Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates | SAN FRANCISCO--(BUSINESS WIRE)--Mar 22, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet med... |
| 17.03.2021 | Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society’s 2021 Annual Meeting | SAN FRANCISCO--(BUSINESS WIRE)--Mar 17, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet nee... |
| 20.02.2020 | Spruce Biosciences Raises $88M in Series B Financing | Spruce Biosciences, a San Francisco, CA-based clinical stage biopharmaceutical company, raised $88m in Series B financing. The round was co-led by Omega Funds and Abingworth with participation from existing investors Novo Holdings and River... |
| 20.02.2020 | Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth | - |
| 20.02.2020 | Spruce nets $88M to push rare disease drug into late-stage trial | In September, Spruce Biosciences reported a phase 2 win for its nonsteroid treatment in a rare endocrine disorder. Now, it’s raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage st... |
| 19.02.2020 | Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth | – Proceeds to advance development of Tildacerfont in Congenital Adrenal Hyperplasia and other indications – Existing Investors Novo Holdings and RiverVest Venture Partners support the deal with new Investors HealthCap, Rock Springs Capital... |
| - | Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society’s 2021 Annual Meeting | SAN FRANCISCO--(BUSINESS WIRE)--Mar 2, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need... |
| - | Spruce Biosciences Strengthens Leadership Team with Appointments of Samir Gharib as CFO and Dasharatha Reddy as VP of Pharmaceutical Development and Manufacturing | San Francisco, Calif. – May 6, 2020 – Spruce Biosciences, a late-stage clinical development company focused on developing and commercializing novel therapies for rare endocrine disorders, today announced the appointments of Samir Gharib, MB... |
Show more